Wegovy 1mg reviews: what actually happens at this stage of treatment

You've hit week nine or ten and you're not sure if 1mg is "working"

This is a question our prescribers hear most weeks. Patients at the 1mg stage often feel something has shifted (appetite is quieter than it was at 0.5mg, meals feel satisfying sooner) but the change can be subtle enough to make people doubt it. That uncertainty is normal. Semaglutide's appetite effect builds cumulatively as the drug reaches steady state at each dose level, and 1mg is genuinely mid-journey, not the destination.

In the STEP 1 trial, which followed adults on the full 0.25mg-to-2.4mg Wegovy schedule for 68 weeks, the average weight loss at the end of the titration period (before participants settled at 2.4mg maintenance) was already meaningful, though the steepest reductions came later. The New England Journal of Medicine published those findings, and they underline why patience at intermediate doses matters. You can read a plain summary on the NHS semaglutide medicines page.

What patients most often notice at 1mg: less interest in finishing a plate, fewer urges to snack between meals, and a reduced pull toward high-calorie foods. Some describe it as the noise around food getting quieter rather than a dramatic switch-off. Physically, energy levels are often more stable than in the first few weeks, when nausea was peaking.

Side effects at 1mg, what tends to ease off and what can still catch you out

The Wegovy side-effect profile is front-loaded. The worst nausea most people experience tends to arrive with the very first dose increase, then again at 0.5mg. By 1mg, the gastrointestinal disruption (nausea, loose stools, belching, reflux) is usually less intense than it was at those earlier jumps, though it doesn't disappear entirely for everyone.

What can still catch people off guard at 1mg: eating too quickly, eating fatty or very rich meals, or drinking alcohol. The stomach empties more slowly on semaglutide, and what felt fine to eat six months ago may now sit uncomfortably. Staying well hydrated matters more than most patients expect.

For most people these effects are mild to moderate and temporary. Serious side effects are uncommon but do exist. The MHRA flagged acute pancreatitis as a known, infrequent but potentially serious risk across GLP-1 medicines, if you develop severe, persistent abdominal pain that spreads to your back, seek medical help promptly rather than waiting. You can report any suspected side effect through the Yellow Card scheme.

Under-18s, anyone who is pregnant, breastfeeding, or trying to conceive should not be on this treatment. Those considerations belong in the prescriber conversation before treatment starts, not partway through.

Should you move to 1.7mg or stay longer at 1mg?

The licensed schedule moves patients from 1mg to 1.7mg after approximately four weeks, then to 2.4mg. But "approximately" is doing real work in that sentence. Titration is a clinical judgement, not a countdown. If side effects at 1mg are still disruptive, a prescriber may recommend staying at this dose for an additional month to let things settle. If tolerance is good and appetite suppression feels partial, moving forward may be the right call.

Neither answer is universally correct. The decision should sit with whoever is clinically responsible for your treatment. If you're self-managing or unsure where things stand, how the Wegovy dose schedule is structured covers the full picture in more detail. Context on how the 1.7mg step tends to compare with this one is covered separately under 1.7mg Wegovy patient experiences.

It's worth knowing that the full licensed efficacy data (around 15% average weight reduction over 68 weeks) is measured across patients who completed treatment through to the 2.4mg maintenance dose. Results at intermediate doses are part of a longer arc. For anyone considering what the higher doses involve, the experiences reported at the 2.4mg maintenance stage give a useful reference point. The newer 7.2mg dose, approved by the MHRA in early 2026, is covered under Wegovy 7.2mg for those wanting to understand where the treatment is heading.

Getting your next supply reviewed and dispensed safely

Wegovy is a prescription-only medicine. Every repeat supply requires a fresh clinical review, that applies whether you're on 1mg, moving to 1.7mg, or reassessing the plan entirely. At nume, a GPhC-registered Independent Prescriber personally reads your consultation before anything is dispensed; there's no automated approval at any dose level.

If cost is on your mind as treatment progresses, how Wegovy pricing works in the UK explains what legitimate private prescriptions include and what to watch for. One transparent price at nume covers the consultation, prescription, and free next-working-day tracked delivery in plain packaging. No subscriptions. Every repeat is re-reviewed.

If you're new to treatment or reviewing your options, the full Wegovy overview covers licensing, eligibility and how semaglutide fits alongside lifestyle changes. A broader look at weight-loss treatment options is available if you're still deciding which medicine is right for you.

Ready to talk through where you are in treatment? Speak to our prescribers through a free consultation, the same day, no waiting list.